$4M Awarded In 1st Pa. Trial Alleging Birth Defect From Topamax Epilepsy Drug

$4M Awarded In 1st Pa. Trial Alleging Birth Defect From Topamax Epilepsy Drug

PHILADELPHIA - A Pennsylvania jury on Oct. 30 found that Janssen Pharmaceuticals Inc. failed to warn about the risk of birth defects from its Topamax epilepsy drug and awarded the injured minor $4 million in damages (April Czimmer, et al. v. Ortho-McNeil-Janssen Pharmaceutica, No. 1105-03459, Pa. Comm. Pls., Philadelphia Co.).

Find full version on lexis Advance®
Access this news story on lexis.com®